Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In the SELECT trial, semaglutide reduced the incidence of major adverse cardiovascular events, including heart attack and stroke, by 20% in individuals with established cardiovascular disease and obesity but without diabetes [10]
reaching 50+ pounds typically requires adding movement at some point
Novo Nordisk reports similar weight loss results during clinical trials from people who used the oral medication and the injectables
Aug 2010;94(3):989-96
Its primary endpoint was measured at week 72, not at week 4 or week 12, and the trial's own structure tells you something: the sponsor and the FDA both expected meaningful change to accumulate across more than a year of treatment
US$ 26.29
US$ 25.49
US$ 25.01
US$ 21.76
US$ 22.10
US$ 22.97
